PUBLISHER: Grand View Research | PRODUCT CODE: 2152257
PUBLISHER: Grand View Research | PRODUCT CODE: 2152257
The global plasmid DNA CDMO market size was valued at USD 753.2 million in 2025 and is projected to grow from USD 892.8 million in 2026 to USD 3,094.4 million by 2033, at a CAGR of 19.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.6% in 2025. Market growth is driven by increasing demand for plasmid DNA in gene therapy, cell therapy, DNA vaccines, and other advanced biopharmaceutical applications, alongside the expansion of development pipelines and growing outsourcing of plasmid DNA development and manufacturing activities.
Moreover, the need for specialized capabilities in plasmid design, bacterial fermentation, downstream purification, formulation, and fill-finish services is increasing the demand for CDMO services. Technological advancements in microbial expression systems, fermentation optimization, purification processes, automation, and analytical testing are improving manufacturing efficiency, product quality, scalability, and batch consistency.
Furthermore, the gene and cell therapy industry has witnessed continued growth in recent years, supported by increasing development activities and advances in plasmid DNA technologies. The growing number of plasmid DNA-based applications across gene therapy, cell therapy, DNA vaccines, and other advanced biopharmaceutical indications is increasing demand for specialized development and manufacturing capabilities. These products require controlled plasmid design, microbial fermentation, purification, formulation, analytical characterization, and GMP-compliant manufacturing processes. Thus, the expansion of plasmid DNA development pipelines is expected to increase demand for specialized CDMO services in the coming years.
In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing plasmid DNA development and manufacturing activities to specialized CDMOs due to technical expertise, specialized infrastructure, and capital requirements associated with in-house production. CDMOs provide plasmid design, process development, fermentation optimization, scale-up, GMP manufacturing, purification, analytical testing, formulation, and fill-finish services. This approach enables developers to access specialized manufacturing capabilities while reducing the need to establish dedicated production facilities. The trend is particularly relevant among emerging biotechnology companies progressing advanced therapy candidates through clinical development and requiring flexible, scalable manufacturing capacity.
Global Plasmid DNA CDMO Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global plasmid DNA CDMO market report based on service, application, manufacturing grade, manufacturing scale, end use, and region: